Amerikanische Gesellschaft für Hirudotherapie

Application of promoting blood circulation and resolving blood stasis in intracerebral hemorrhage: a traditional method gradually moving toward modern stroke care

Review published in J Tradit Chin Med (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewSpeichel-PharmakologieKlinische StudienArzneimittelentwicklungDingshan Z et al. · Journal of traditional Chinese medicine, 2025

Abstract

Intracerebral hemorrhage (ICH) is a significant and growing threat to human health, with increasing incidence. Promoting blood circulation and removing blood stasis therapy (PBCRBS), a Traditional Chinese Medicine therapy, can be an adjuvant therapy to benefit patients with ICH by improving clinical efficacy. However, in theory, using PBCRBS to treat ICH carries the risk of hematoma enlargement and rebleeding, which has led to controversy over its application in ICH treatment. To demonstrate the effectiveness and safety of PBCRBS in treating ICH, this review first analyzes the pathological and physiological basis of ICH and secondly, the cascade of response after ICH and the involvement of cytokines and signaling pathways in this process. Finally, experimental and clinical studies on the treatment of ICH with PBCRBS over the past decade were retrieved from the PubMed and China National Knowledge Infrastructure databases, and the content of these studies was used to summarize commonly used herbs with PBCRBS effects and their mechanisms of action. Through analysis, hypertension has been identified as the most common cause of ICH. Heme, interleukin, reactive oxygen species, coagulation promoting particles and other induced mass effects, inflammation, oxidative stress, and coagulation cascade reactions lead to brain damage following ICH. This review includes 56 experimental studies and 83 clinical studies summarizing 28 commonly used herbs, demonstrating the positive impact of PBCRBS as an adjuvant therapy for ICH. In summary, PBCRBS appears effective and safe for treating ICH.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansCerebral HemorrhageDrugs, Chinese HerbalAnimalsBlood CirculationMedicine, Chinese Traditional

Zusammenfassung

Review of traditional Chinese medicine principles for promoting blood circulation and resolving stasis in intracerebral hemorrhage, including leech-based formulations. Maps the translational bridge between TCM and modern stroke care.

Warum dies für die Hirudotherapie relevant ist

This review examined the Traditional Chinese Medicine therapy of promoting blood circulation and resolving blood stasis (PBCRBS) as adjuvant treatment for intracerebral hemorrhage, analysing 56 experimental and 83 clinical studies covering 28 commonly used herbs. It addressed the theoretical controversy that pro-circulatory agents might worsen hematoma expansion, concluding PBCRBS appears effective and safe. Relevance to ASH is indirect at best: the abstract makes no mention of leeches, hirudin, or leech-derived substances, and the focus is on Chinese herbal mixtures. No leech-specific therapeutic data are presented, so the connection to hirudotherapy is not established by this abstract.

Zitation

Application of promoting blood circulation and resolving blood stasis in intracerebral hemorrhage: a traditional method gradually moving toward modern stroke care.

Dingshan Z et al. · Journal of traditional Chinese medicine, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.